$14.57
+0.33 (+2.32%)
Open$14.53
Previous Close$14.24
Day High$14.76
Day Low$14.26
52W High$34.10
52W Low$7.78
Volume—
Avg Volume115.8K
Market Cap210.78M
P/E Ratio—
EPS$-1.56
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+133.7% upside
Current
$14.57
$14.57
Target
$34.05
$34.05
$25.54
$34.05 avg
$45.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 64.12M | 62.89M | 59.76M |
| Net Income | 10.06M | 8.97M | 9.50M |
| Profit Margin | 15.7% | 14.3% | 15.9% |
| EBITDA | 19.32M | 16.62M | 17.12M |
| Free Cash Flow | 7.72M | 11.60M | 9.03M |
| Rev Growth | -9.0% | -7.6% | +0.6% |
| Debt/Equity | 0.70 | 0.55 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |